Results 71 to 80 of about 605,155 (296)

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

A Retrospective Analysis Comparing the Dosimetric Parameters of Two Rectum-Sparing Techniques During Intracavitary Brachytherapy with Tandem-Ring Applicators for Cervical Cancer

Cancer Management and Research
Siddharth Vats,1 Shabnum Thakur,2 Manish Gupta,1 Vineet Kumar,3 Lalit Chandrakant,1 Muninder Negi,4 Parul Sharma,1 Vikas Fotedar,1 Purnima Thakur,1 Deepak Tuli,1 Poorva Vias,2 Jyoti Sharma,5 Anup Negi,6 Shilpa Kaushal,7 Mrinalini Upadhyay,1 Naina Negi,1 ...
Vats S, Thakur S, Gupta M, Kumar V, Chandrakant L, Negi M, Sharma P, Fotedar V, Thakur P, Tuli D, Vias P, Sharma J, Negi A, Kaushal S, Upadhyay M, Negi N, Sharma A, Azad A, Parihar N, Verma D   +19 more
doaj  

Radiotherapy [PDF]

Journal of Thoracic Oncology, 2010
Baggstrom, Maria Q., Govindan, Ramaswamy
openaire   +2 more sources

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Image guided high-dose-rate brachytherapy versus volumetric modulated arc therapy for head and neck cancer: A comparative analysis of dosimetry for target volume and organs at risk

Radiology and Oncology, 2018
The aim of the study was to present dosimetric comparison of image guided high-dose-rate brachytherapy (IGBT) with volumetric modulated arc therapy (VMAT) for head and neck cancer regarding conformity of dose distribution to planning target volume (PTV ...
Akiyama Hironori, Pesznyák Csilla, Béla Dalma, Ferenczi Örs, Major Tibor, Polgár Csaba, Takácsi-Nagy Zoltán   +6 more
doaj   +1 more source

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

The Prognostic Value of Combined Systemic Immune-Inflammatory Index (SII) and Prognostic Nutritional Index (PNI) in Solid Tumor

Cancer Management and Research
Yan Zhang, Min Tang, Qian-Hui Gu, Li-Na Zhou, Min-Bin Chen Department of Oncology & Radiotherapy, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, 215300, People’s Republic of ChinaCorrespondence: Min-Bin Chen, Department of ...
Zhang Y, Tang M, Gu QH, Zhou LN, Chen MB
doaj  

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Adaptive radiotherapy: The Elekta Unity MR-linac concept

Clinical and Translational Radiation Oncology, 2019
Background and purpose: The promise of the MR-linac is that one can visualize all anatomical changes during the course of radiotherapy and hence adapt the treatment plan in order to always have the optimal treatment.
Dennis Winkel, Gijsbert H. Bol, Petra S. Kroon, Bram van Asselen, Sara S. Hackett, Anita M. Werensteijn-Honingh, Martijn P.W. Intven, Wietse S.C. Eppinga, Rob H.N. Tijssen, Linda G.W. Kerkmeijer, Hans C.J. de Boer, Stella Mook, Gert J. Meijer, Jochem Hes, Mirjam Willemsen-Bosman, Eline N. de Groot-van Breugel, Ina M. Jürgenliemk-Schulz, Bas W. Raaymakers   +17 more
doaj